Instructions to Authors
Papers will be considered for publication if they are relevant to any aspect of drug action in humans. Submission of a manuscript to BJCP will be taken to indicate that
the content of the manuscript is original and that it has not been published or accepted for publication, either in whole or in part, other than as short abstracts, communications or conference proceedings;
no part of the manuscript is currently under consideration for publication elsewhere;
all authors have seen and approved the final version of the submitted paper;
authors have, if necessary, obtained permission to publish from their employers or institutions;
approvals are held from any persons acknowledged, or cited as having provided personal communication; and
permission has been obtained to use any copyrighted material, such as reproducing a figure from another article, in print and electronic forms, and that the source of the material has been acknowledged.
BJCP publishes papers of various kinds including Original Research Articles, Methods in Clinical Pharmacology, Reviews (including Systematic Reviews), Commentaries, Opinion, Education papers and Letters to the Editor.
We publish papers describing experimental pharmacology in humans. We do not, however, normally accept papers that describe just pharmacokinetics without a measure of the pharmacodynamics of a new medicine. An example is a First-in Human study in which only pharmacokinetics and side effects are reported when quantitative pharmacodynamics could have been reported. This is described in one of our editorials.
Original research articles are grouped under headings, including Clinical trials, Drugs in Pregnancy and Lactation, Drug Interactions, Drug Metabolism, Drug Safety, Human Toxicology,Methods in Clinical Pharmacology, New Drug Mechanism, Paediatric Clinical Pharmacology, Pharmacodynamics (PD), Pharmacoeconomics, Pharmacoepidemiology, Pharmacogenetics, Pharmacokinetics (PK), PK-PD relationships, Therapeutics, and Translational Research. Authors are invited to suggest which heading they feel their manuscript would best fit, and may suggest additional headings if they so wish.
Investigations of human subjects are expected to have been conducted in accordance with Good Clinical Practice (GCP). GCP is an international quality standard that defines investigator responsibilities, including, among others, qualifications, resources, providing medical care to trial participants, communication with the research ethics committee, protocol, informed consent, data integrity and reporting (http://ichgcp.net/4-investigator). Everyone involved in the conduct of clinical research must be competent to perform their tasks, qualified by education, training and experience. According to GCP guidelines (or in GCP terminology) the Principle Investigator of a clinical study should be a medical doctor and that person is responsible for the execution of, and is involved in running of, the study. BJCP expects clinical studies to be conducted according to GCP guidelines and also logically expects the GCP defined Principle Investigator of the study to be one of the authors. If this is not the case for a submission, a clear statement on why the PI has not been included must be supplied with your submission.
Please note that authorship of a BJCP paper must follow ICJME guidelines – ie that all authors must fulfil all the criteria below:
Substantial contributions to the conception or design of the work; or the acquisition, analysis, or interpretation of data for the work; AND
Drafting the work or revising it critically for important intellectual content; AND
Final approval of the version to be published; AND
Agreement to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.
Preparing and submitting a manuscript
Once you have read these guidelines in full, please go here to submit your manuscript.
You will need to submit three documents:
- covering letter that includes specific statements; and
- a competing interests statement formatted as per our guidelines.
If your paper is accepted, you will subsequently be required to submit both a table of key links (targets and ligands) to the BPH/IUPHAR Guide to Pharmacology, and a copyright transfer agreement form signed by the corresponding author. You will be taken to the Wiley Author Licensing Service to complete this, and full guidance is given there. Please see more below.
Papers must be written in clear, concise UK English. Avoid jargon and neologisms.
Regrettably, the Journal is unable to undertake major corrections to language, which is the responsibility of the author. Because there should be no barriers to getting your research published, however, manuscripts are often returned for English language and formatting issues. Thus, a pre-acceptance Editing Service (comprising English language editing, translation services, manuscript formatting and preparation) is available and can provide you, the author, with expert help to ensure your manuscript is ready for submission. Japanese authors can also find a list of local English improvement services at http://www.wiley.co.jp/journals/editcontribute.html . All services are paid for and arranged by the author, and use of one of these services does not guarantee acceptance or preference for publication.
Note that Japanese fonts must not be used in the creation of files (the standard Adobe Acrobat program is not compatible with these fonts).
Manuscript documents should be typed in double spacing and should be page numbered. Line numbers must also be added to your manuscript before submission.
A separate title page should be included (see below). The submitting author need not be the same as the corresponding author.
Authors may find this resource useful.
Authors should ensure that they have provided the following information, when appropriate:
A cover letter detailing originality of the manuscript and agreement of all authors and also identifying the Principal Investigator who undertook any human studies reported.
A title page including a title of no more than 150 characters, all author names and affiliations, and the corresponding author contact information. Also including a running head, keywords and word count.
A structured summary of no more than 250 words, including estimates of relevant treatment effects, along with 95% CIs or other measures of variability, when appropriate.
‘What is known about this subject’ and ‘What this study adds’ statements (up to three bullet point sentences for each).
A statement (in Methods) of ethics committee approval and subject consent including the name of the ethics committee and the approval number or identification code.
Confidence intervals (CI) of relevant differences between major end points.
Details of precision, accuracy, sensitivity, and specificity for drug/metabolite assays.
A statement declaring any competing interests, or declaring that there are no competing interests.
Acknowledgement of financial and other support.
Preprints of relevant unpublished papers.
Figures and tables must be submitted as separate files, and guidance on preparing artwork can be found here. The following formats are accepted: gif, jpg, bmp, tif, pic (figures) and as Word and Excel files (tables). PDF and Powerpoint files are not ideal formats and should be avoided if possible.
The main text file must contain the title page, summary, text, references, and figure legends.
Manuscripts in rich text format should not contain word processor styles (for example bold, italics, justification).
Please include in your covering letter the following:
Statements regarding the originality of the work and agreement of all authors to its publication
Papers will not be approved for review unless accompanied by a statement, in the covering letter, that they have not been, and will not be published, in whole, or in part, in any other journal, and that all the authors have agreed to the contents of the manuscript in its submitted form. If authors have a problem in contacting a co-author for approval, the reason for this should be explained in the letter and may subsequently be discussed via email with the relevant Senior Editor.
If there is any overlap between a submitted manuscript of an original paper and a paper that is being submitted elsewhere, the submitting author should draw this to the attention of the Editors in the submission covering letter and enclose a copy of the relevant submitted paper(s).
If there is any overlap with a paper that has already been published elsewhere (including online publication), including use of the same subjects or repetition of any data, that paper must be referred to and cited in full.
If your manuscript refers to unpublished data (see section below “References to data on file”), you should obtain (and provide the Editorial Office with a copy) written permission to mention a responsible individual (e.g. “Prof X...contact address firstname.lastname@example.org) or should identify a department in a company that can be contacted, with a contact address.
For ALL papers describing investigations of human subjects (e.g. Research Papers) please indicate which of the authors was the Principal Investigator. (If the Principal Investigator is not an author of the paper, please explain why not.) BJCP has a policy of not accepting papers of which a person with final medical responsibility is not an author: please see the recent Editor’s View.
Authors can, if they choose, facilitate the review process by providing, as part of the electronic submission process via ScholarOne, the names, institutions and email addresses of up to two suggested reviewers, on the understanding that the Editors are not bound by any such nomination, and that the Editors will check the credentials of these nominated individuals carefully to ensure optimum ethical standards. Opposed reviewers may also be supplied.
Conflicts of interest
All authors must declare any potential conflicts of interest. The corresponding author of an article acts as guarantor and must ensure that this is criterion is fulfilled and a full conflicts of interest statement is supplied to the Publisher.
Papers will not be rejected because there is a competing interest: the aim of funding and conflicts of interest statements is not to eradicate conflicts of interest (they are common); it is so that BJCP articles are fully transparent and ethical.
A conflict of interest exists when a primary interest (such as the validity of research) might be influenced by a secondary interest (such as financial gain or personal rivalry). It may arise for the authors of a BJCP article when they have a financial interest that may influence their interpretation of their results or those of others. Financial interests are the easiest to define and they have the greatest potential to influence the objectivity, integrity or perceived value of a publication. They may include any or all, but are not limited to, the following:
- Personal financial interests: Stocks or shares in companies that may gain or lose financially through publication; consultant or speaker fees; other forms of remuneration from organisations that may gain or lose financially; patents or patent applications whose value may be affected by publication.
- Employment: Recent, present or anticipated employment of you or a family member by any organization that may gain or lose financially through publication of the paper.
- Gifted drugs, materials or devices not commercially available
- Patent rights
- Consultancy work (past or present).
Examples of appropriate conflicts of interest statements would be
- This work was supported by the NIH (grant to AB and CD).
- This work was supported by a grant from Big Pharma Inc. (to AB) and equipment was donated by Small Pharma Inc. EF received a graduate studentship award from the University of xxxxx.
- AB declared no other relationships or activities that could appear to have influenced the submitted work.
- This work was supported by a grant from the National Institutes of Health, USA (DKxxxx to AB).
- This work was supported by the NIH (grant to AB and CD).
- This work was supported by a grant from Big Pharma Inc. (to AB) and equipment was donated by Small Pharma Inc. EF received a graduate studentship award from the University of xxxxx.
For papers where no conflicts of interest or funding are declared, a default statement is added to that paper.’
The peer and publication process
BJCP operates a single-blind peer-review process using a body of expert peer reviewers. Correspondence related to published research in BJCP is not usually subject to peer review, but is shared with the authors of the original paper prior to any publication, with a right to reply. All substantive papers — ie original research and reviews (commissioned and non-commissioned), including those published under our open access programme OnlineOpen — undergo the same rigorous and consistent peer review process.
Once submitted, a manuscript will first be checked by the Editorial Office to ensure all elements have been submitted. If any required documentation is not present, the Editorial Office will return the manuscript to the authors and request any missing information or material.
Once a paper is accepted, it is published within a few days on the journal website in the format of the final accepted version, i.e. as a PDF of the Word version. This final accepted version, known as an ‘Accepted Article’ is fully citable (and has a perpetual Digital Object Identifier [DOI]). Accepted articles are replaced by Early View (see below) and then the final version of record once published in an issue.
BJCP publishes Early View articles, which are complete full-text articles published online in advance of their publication in an issue. Articles are therefore available as soon as they are ready, rather than having to wait for the next scheduled issue. Early View articles are complete and final. They have been fully reviewed, revised and edited for publication, and the authors’ final corrections have been incorporated. Because they are in final form, no changes can be made after online publication. The nature of Early View articles means that they do not yet have volume, issue or page numbers, so Early View articles cannot be cited in the traditional way. They have the same a DOI as their Accepted Article counterpart, which allows the article to be cited and tracked before it is allocated to an issue. After issue publication, the DOI remains constant and valid and can continue to be used to cite and access the article.
We strongly encourage all authors to register with ORCID, which provides a persistent digital identifier for individual researchers that, through integration in key research workflows such as manuscript and grant submission, supports automated links between a researcher and his/her professional activities, ensuring that his/her work is recognised. On submission, you will be given an opportunity to link your ORCID number with your Scholar One account.
Publishing your paper open access
OnlineOpen, Wiley’s open access programme , is available to BJCP authors who wish to make their article available (immediately) to non-subscribers on publication, or whose funding agency requires grantees to archive the final version of their article. With OnlineOpen, the author, the author's funding agency, or the author's institution pays a fee to ensure that the article is made available to non-subscribers upon publication via Wiley Online Library, as well as deposited in the funding agency's preferred archive. Please see here a helpful guide to compliance. See here for open access policies by funder, and please see below more on copyright.
Prior to acceptance there is no requirement to inform the Editorial Office that you intend to publish your paper OnlineOpen if you do not wish to. All OnlineOpen articles are treated in the same way as any other article. They go through the Journal's standard peer-review process and will be accepted or rejected based on their own merit.
Any authors wishing to have their paper published Online Open will be required to complete the payment form.
Copyright – using the Wiley Author Licensing Service
The author identified as the formal corresponding author for an accepted paper will, on acceptance of their article, receive an email prompting them to login into Author Services, where, via the Wiley Author Licensing Service (WALS), he/she will be able to complete the relevant copyright or licence agreement on behalf of all authors on the paper.
For authors signing the copyright transfer agreement
If the corresponding author does not select the OnlineOpen option in WALS, he/she will be presented with the copyright transfer agreement (CTA) to sign. (See here for further details.)
For authors choosing OnlineOpen
If the OnlineOpen option is selected the corresponding author will have a choice of the following Creative Commons Licences
- Creative Commons Licence Open Access Agreements (OAA)
- Creative Commons Attribution Non-Commercial Licence OAA
- Creative Commons Attribution Non-Commercial -NoDerivs Licence OAA
If a corresponding author selects the OnlineOpen option and his/her research is funded by The Wellcome Trust and members of the Research Councils UK (RCUK) he/she will be given the opportunity to publish the article under a CC-BY licence supporting compliance with Wellcome Trust and Research Councils UK requirements. For more information on funder policies, please see here and here. For a useful guide to ensuring compliance, see here.
Using copyrighted material
It is the author’s sole responsibility to obtain permission to use copyrighted material, including print and electronic forms, in a paper, in advance of submission and to acknowledge fully the source of the material.
Original Research Articles
Papers should be concise and consideration should be given to using supporting information (see http://authorservices.wiley.com/bauthor/suppmat.asp for more information about our Supporting Information service). Most original research articles published in BJCP are between 3000 and 4000 words (for Introduction, Methods, Results and Discussion only). Please refer to a recent issue for examples of length that we regard as appropriate, which varies with the complexity and importance of the study. If you believe your original research paper is going to significantly exceed 4000 words, we require justification for this with your submission letter.
When writing your paper, original research papers should generally be divided into the following sections: Title Page (including PI Statement), Structured Summary, Introduction, Methods, Results, Discussion, Acknowledgements, References, tables and legends to figures (Please remember that figures must be submitted as separate files). In addition authors should provide material for the following 2 sections, placing this after the Structured Summary:
Section 1: What is already known about this subject: In up to three short bullet point sentences (not more than 50 words in total) summarise the state of scientific knowledge on this subject before you did your study and say why this study needed to be done.
Section 2: What this study adds: In up to three short bullet point sentences (not more than 50 words in total) give a simple answer to the questions “What do we now know as a result of this study that we did not know before?” and “What take-home-message do you want to impart to the readers?”
These two statements should be succinct, accurate and specific.
All Research Papers require a list of author contributions.
Review articles on a wide range of topics appear regularly in the Journal. Articles may be unsolicited, or may be commissioned by the Reviews Editor. Either kind may be single papers or, by prior agreement with the Editor, part of a themed series. Contributors are welcome to submit single review articles directly (systematic reviews are especially welcome). Most reviews should be between 2500 and 3000 words, should be fully referenced, and if judged potentially suitable will undergo peer review. Each review should include a summary but not the boxes (“what is known”/ “what this adds”) that are required only for original research articles. They will be subject to the other requirements of an original research paper.
From time to time the Journal will publish themed issues, including review articles and related original research papers. Authors who want to suggest a theme for a special issue should contact the Editor-in-Chief.
The Journal welcomes systematic reviews. The manuscript should provide a concise account of the methods used, and concentrate on highlighting key aspects of interest and relevance to clinical pharmacologists, under the following headings: Structured Summary, Introduction, Methods, Results, Discussion, and Conclusion.
Introduction This should describe the background (e.g. relevant clinical and pharmacological issues) and the scope and aim of the review. What was the reason for the review? The strengths and weaknesses of the existing literature should be briefly defined, earlier reviews identified and the need for the present paper explained.
Methods Study selection is particularly important (search strategy, type of intervention/exposure, types of studies included, types of outcomes, types of participants); include information on any data extraction and synthesis (statistical techniques and use of a quality assessment tool, if any).
Results The key characteristics of the included studies and the main outcome measures; discuss variation within and between studies.
Discussion Compare the findings with existing knowledge; outline the limitations of the review.
Conclusion Summarize the key findings and the implications for clinical pharmacology and/or practical drug therapy.
Letter to the Editor
Comments on previously published papers, items of topical interest, and brief original communications will be considered under this heading. The length, including references, should not exceed 800 words, plus one figure or table. The letter should NOT be divided into sections.
Case reports must be submitted as Letter to the Editor)
The Journal generally does not publish case reports as full papers but may do so as Letters to the Editor. As for other letters the length, including references, should not exceed 800 words, plus one figure or table. Such case reports (for example adverse drug reactions or interactions) should include some novel aspect of drug action in man (for example a new adverse reaction or one that gives insight into a mechanism or method of management). Such reports may include single cases or short case series. Notes and guidelines on the format for publishing such reports, including a structured summary, will be found at http://www.bmj.com/content/suppl/2003/06/19/326.7403.1346.DC1.
Short Reports are published by the journal. These are short original articles, with a maximum word count of 1.500 to 2,000 words. The summary should be unstructured and comprise no more than 150 words. There should be no more than 3 figures and tables (in any combination). Short Reports should be structured in the same way as original articles (Introduction, Methods, Results, Discussion) and should include statements on What is already known about this subject and What this study adds.
Appealling Editorial Decisions
An author may appeal an editorial decision by directly contacting the Editor-in-Chief through the Editorial office.
An appeal will override an earlier decision only when new information becomes available (for example, additional factual input by the authors, revisions, extra material in the manuscript, or appeals about conflicts of interest and concerns about biased peer review).
The Editor-in-Chief will mediate all exchanges between authors and peer reviewers during the appeal.
The Editor-in-Chief's decision following an appeal is final.
If the Editor-in-Chief has a conflict of interest and cannot review the appeal, this will be delegated to an independent Senior Editor.
When a drug can exist as stereoisomers or diastereomers (for example geometrical isomers), the form of compound studied must be designated as follows in the methods section.
In the case of racemates the prefix rac- should precede the drug name (for example rac-propranolol).
When possible the absolute configuration of enantiomers should be indicated (for example (S)-warfarin).
Similarly, geometrical isomerism should be indicated by the prefixes Z/E or cis/trans. When appropriate, the interpretation of data obtained using mixtures of isomers should take account of stereochemical aspects.
Prescribed drugs should be designated by an International Non-proprietary Name (recommended, rINN, or proposed, pINN). If such a name is not available, a drug should be designated by its British Approved Name (BAN; for example hyoscyamine) or its chemical name (for example glyceryl trinitrate).
When a mixture of drugs has a combination BAN (for example co-trimoxazole, co-fluampicil), that should be used.
For brevity, a company's code name may be used, but in that case the full chemical name or a figure showing the structure of the drug should be given in the introduction or a reference provided that gives this information.
Some mediators with well established common names (e.g. prostacyclin) are also prescribed as licensed preparations with an rINN (e. g. epoprostenol). In such cases the rINN should be used in the context of therapeutic use. Sometimes English and American usage varies, as with adrenaline / epinephrine and noradrenaline / norepinephrine. “Adrenaline / noradrenaline” relate clearly to terms such as “noradrenergic”, “adrenergic” and “adrenal gland” but we will accept the term preferred by authors.
SI units (mass or molar units) should be used. If other units are used, a conversion factor should be included in the Methods section.
A set of standard symbols in pharmacokinetics and pharmacodynamics can be found here.
The title page should include
the title giving an informative and accurate indication of the content of the paper. It should be no longer than 150 characters, including spaces;
the names, positions, and addresses of the authors;
the name and e-mail address of the submitting author and the corresponding author, if different;
a running head of no more than 75 characters, including spaces;
keywords (these are used to identify potential referees and as indexing terms);
the word count, excluding the title page, summary, references, tables, and figures;
the numbers of tables and figures.
In order to ensure correct citation of your article on PubMed, should your article be accepted for publication, please include spaces in-between author's initials on the title page of your manuscript, e.g. A E Smith. If author's initials do not appear on the title page of your manuscript according to these guidelines they may appear incorrectly on PubMed until your article has been typeset and published in an issue.
The text must be preceded by a structured summary, including the following headings:
- Results (some numerical data, including confidence intervals on differences, when appropriate, must be included)
The summary should be a maximum of 250 words; abstracting services truncate summaries that are longer. It should be couched in terms that will be understood by most readers of the Journal.
Authors should include details of the precision, accuracy, sensitivity, and specificity of an analytical method used to measure drugs, metabolites or biomarkers or refer to other publications in which the information is given.
Precision is a measure of random error, usually expressed as the coefficient of variation.
Accuracy is a measure of systematic error, also called bias; it can be expressed as the percentage difference between the result for a test sample and the reference value for that compound.
Sensitivity or lower limit of quantification.
Specificity is the extent to which the method does not detect compounds other than those intended.
In the Methods section statistical methods should be described clearly, in particular for the main analyses. Authors should state which data they had planned to analyse as primary endpoints to investigate their primary objective, and whether they had been analysed as inferential analysis (i.e. with a pre-specified statistical hypothesis) or for exploratory reasons.
Derivations of endpoints, e.g. change from baseline or relative frequencies, should be clearly specified. Covariates that have been used in the statistical analysis (e.g. ANCOVA) should be identified, with a justification for their inclusion (e.g. a reference).
The statistical section should clarify whether the aim of the study was exploratory or confirmatory. In confirmatory trials, a detailed sample size determination should be provided. Strategies to account for multiple testing should be outlined where relevant.
In exploratory trials, the sample size may be justified in terms of expected precision of the estimates parameters of interest. If study size has been chosen based on other criteria (e.g. practical constraints), this should be stated.
In the Results section, measures of variability/uncertainty, such as confidence intervals, should be provided, where relevant for important endpoints. The use of p-values to demonstrate statistical significance should be limited to key endpoints.
Equivalence or non-inferiority of treatments should only be claimed if a statistical margin (e.g. bioequivalence margins of 80%-125%) had been pre-specified in the protocol, and the study had been powered to demonstrate these objectives. It should be avoided to interpret the absence of statistically significant differences as equivalence between treatments.
The Editors may utilize specialist statistical referees for manuscript review where necessary.
Tables should generally not have more than 85 characters to a line (counting spaces between columns as 4 characters) and certainly not more than 110 characters to a line, unless absolutely unavoidable. Each table should be typed on a separate page and be in an editable format (doc or xls).
Figures and Use of Colour
Please provide high quality figures suitable for the journal’s production processes. Use of colour (free to authors) is encouraged when it improves the clarity of the message conveyed.
Authors should consider presenting data on the same scale as the statistical analysis, i.e. when the logarithmic transformation was used during the analysis, the corresponding data should also be presented on logarithmic scale. For concentration-time profiles it might sometimes be useful to present both the initial and the terminal phase using a larger graph as well as an inset. In multi-panel figures it is recommended to align the corresponding axes.
To enhance the presentation of their articles, authors are encouraged to use colours as presented in the examples. The suggested colours all work together and should be clear to those readers who are colour-blind. With certain figures when it is helpful to strongly differentiate between sets of results, the first colour of each pair should initially be used (example), with the corresponding extra colours introduced as necessary. Although white backgrounds are generally advisable, if necessary a suggested background colour that works both with the overall look of the journal, and the proposed colour palette is illustrated (example).
Digital files should be prepared in accordance with the instructions that will be found at http://authorservices.wiley.com/bauthor/illustration.asp. The eps format (illustrations, graphs, annotated artwork; minimum resolution 800 dpi) and tif format (micrographs, photographs; minimum resolutions 300 dpi) are recommended, although in some cases other formats can be used.
References should be cited using the Vancouver style (see examples below; for detailed instructions see http://www.icmje.org).
References in the manuscript text should appear as numbers in square brackets.
The reference list should show the references in numerical and not alphabetical order, and should include the names of the first six authors (plus et al if there are more than six), the full title of the article, the title of the publication (abbreviated as in Medline or PubMed), the year, the volume number, and the first and last page numbers.
References to books should include the names of the editors, the edition number, when appropriate, and the place of origin and the name of the publisher.
The accuracy of the references is the responsibility of the author. Referencing should be thorough but not excessive. Older literature that has been well reviewed can be referred to indirectly by citing the review(s).
Johnson TN, Rostami-Hodjegan A, Tucker GT. A comparison of methods to predict drug clearance in neonates, infants and children. Br J Clin Pharmacol 2004; 57: 677-8.
Metters J (editor). Independent Steering Committee Report of an Independent Review of Access to the Yellow Card Scheme. London: The Stationery Office, 2004.
Hoffman BB, Lefkowitz RJ. Beta-adrenergic receptor antagonists. In: The Pharmacological Basis of Therapeutics, Eighth Edition, eds Gilman AG, Rail TW, Nies AS, New York: Pergamon Press, 1990: 229-43.
Accepted articles and Early view
References to papers published as Accepted Articles should be cited thus: Ferro A. Paediatric prescribing: why children are not small adults. Br J Clin Pharmacol 2015. doi: 10.1111/bcp.12540.
References to archived data supporting the publication should be cited thus: Brown, LJ; Year. Dataset title; Data repository or archive; Version (if any); Persistent identifier (e.g. DOI).
References to data on file
Any assertions within a submitted manuscript that are backed up by reference to unpublished data should be clearly noted as such in the body of the manuscript and should give a clear direction to the reader as to how they might request this data: e.g. ‘ACME34178 is not metabolised by CYP3A4 (unpublished data on file, ACME Drug Co. Ltd., Didcot, UK)’, ‘Drug Z is known to partition extensively into erythrocytes (personal communication from Prof. X, University of Y)’
If making such a reference to unpublished data the author should obtain (and provide the Editorial Office with a copy) written permission to mention an individual (Prof X) or should identify a department in a company that can be contacted with an address (Department of Drug Metabolism, ACME Drug Co, email@example.com) and the permission should come from the head of that department or their designate.
All support, financial or otherwise, for any work described should be acknowledged, with the exception of support from employing institutions identifiable from the title page. This includes CRO contributions to any trials, and support with medical writing, for PK, PD and statistical analysis. Authors are reminded that if they want to acknowledge the assistance of an individual, it is courteous to ask the individual’s permission to do so.
Supporting Information can be a useful way for an author to include important but ancillary information with the online version of an article. Examples of Supporting Information include additional tables, data sets, figures, movie files, audio clips, 3D structures, and other related nonessential multimedia files. Supporting Information should be cited within the article text, and a descriptive legend should be included. It is published as supplied by the author, and a proof is not made available prior to publication; for these reasons, authors should provide any Supporting Information in the desired final format.
For further information on recommended file types and requirements for submission, please visit: http://authorservices.wiley.com/bauthor/suppinfo.asp
Once your article is accepted
If your article is accepted, you will be asked to submit both a copyright form (see above) and a table of links to the table of links to the BPS/IUPHAR Guide to Pharmacology.
Linking to the BPS/IUPHAR Guide to Pharmacology
Nomenclature used in your article should follow that of the BPS/IUPHAR Guide to Pharmacology. Should your manuscript be accepted, for all key ligands and targets cited in your manuscript, you will be asked to add links (within the body of the text, at first mention) from your article to the Guide to Pharmacology. You will be asked by the Editorial office to also provide a list of these hyperlinked ligands and targets. This list will be for checking purposes only, by the journal copy editors. You will be given clear instructions on how to carry out this requirement, but you can also find instructions here.
A video abstract can be a quick way to make the message of your research accessible to a much larger audience.
In 2017, Wiley, our Publishers, and its partner Research Square, will be offering, on a trial basis, a service of professionally produced video abstracts, available to authors of 5 articles selected by the journal. You can learn more about it at www.wileyauthors.com/videoabstracts . Authors of papers selected for this service will be contacted through the editorial office.
Proofs will be sent to the corresponding author and should be returned within 3 days of receipt to the Production Editor. The corresponding author will receive an e-mail alert containing a link to a secure web site. A working e-mail address must therefore be provided for the corresponding author. In the absence of the corresponding author, please arrange for a colleague to access the e-mail to retrieve the proofs.
Acrobat Reader will be required in order to read the proof file and can be downloaded (free of charge) from the following website: http://www.adobe.com/products/acrobat/readstep2.html. This will enable the file to be opened, read on screen, and printed out in order that corrections can be made.
Further instructions will be sent with the proof. In your absence, please arrange for a colleague to access your e-mail to retrieve the proofs.
Corrections should be kept to a minimum. Extensive changes may be charged to the author.
Once proofs have been corrected the paper will be published online in the next available issue. The online version is definitive and there will be no further opportunity for correction. The date of publication of the article is the date of its first appearance online as an Accepted Article.
Author Services enables authors to track their article once it has been accepted through the production process to publication online and in print. Submitting authors can check the status of their articles online and choose to receive automated e-mails at key stages of production, so that they don’t need to contact the production editor to check progress. Visit http://authorservices.wiley.com/bauthor for more details on online production tracking and for a wealth of resources, including FAQs, tips on article preparation, submission, and more.
Through Author Services, all successful authors will be invited to join Kudos, to assist with enhancing the value of their research, and they will also have the opportunity to share the version of record of their accepted article with up to ten colleagues.
Free access to the final PDF offprint of your article will be available via author services only. Please therefore sign up for Author Services if you would like to access your article PDF offprint and enjoy the many other benefits the service offers. Although the journal is now published online only, paper offprints can be ordered at prices quoted on the order form that accompanies the proofs, provided that the form is returned with the proofs.
These are normally dispatched within 3 weeks of publication of the issue in which the paper appears; however please note that they are sent by surface mail, so overseas orders may take up to 6 weeks to arrive. PDF offprints are sent to the requesting author at his/her first e-mail address on the title page of the paper, unless advised otherwise; please therefore ensure that the name, address and e-mail address of the corresponding author are clearly indicated on the manuscript title page if he or she is not the first author of the paper.
The BJCP Annual Prize for Authors in Training
The British Pharmacological Society awards an annual prize of £1,000 for the best paper published in BJCP during an academic year. Those eligible will be Registrars in Clinical Pharmacology and Therapeutics (usually ST3s and above) registered for Higher Medical Training in the UK and the Republic of Ireland and those in comparable training schemes (including PhD schemes) elsewhere. Potentially eligible authors will be contacted by the Editorial Office at the end of each academic year and invited to complete an application form, giving information about the provenance of the work and the precise role played by the potential award winner.
The Editors will judge all entries, but they may call for expert assistance in making their decision. Their decision is final.
Transfer to other British Pharmacological Society (BPS) journals
Pharmacology Research & Perspectives (PR&P), an open access journal, is jointly edited on behalf of the BPS and the American Society of Pharmacology and Experimental Therapeutics (ASPET). The BPS also publishes British Journal of Pharmacology (BJP). The Editors of BJCP might consider that a submitted manuscript is out of scope and more suitable for consideration by BJP or PR&P. If so, the Editors will offer authors the opportunity to transfer their manuscript to the Editorial office of its sister journals for consideration.
Please see above and here for full guidance on all issues related to Publication Ethics. The Journal subscribes to COPE's code of conduct and its Ethical Policy is based on COPE guidelines. The journal will adhere to COPE flowcharts for all matters related to research misconduct.
Consent must be informed. The ethical aspects of all studies involving human subjects will be particularly noted when assessing manuscripts. The methods section should include a statement that the subjects consented to the study after full explanation of what was involved; it should indicate whether or not consent was obtained in writing.
The Methods section should contain a statement that, when applicable, explicit patient consent was obtained for the use of tissue for research. Local laws (e.g. the Human Tissue Act) should be adhered to. Where potentially relevant (e.g. functional investigations) details of the donors’ drug histories must be provided. Drug history must include any anaesthetic used for the biopsy.
BJCP requires that clinical trials are prospectively registered in a publicly accessible database. Please include the name of the trial register and your clinical trial registration number at the end of your abstract. If your trial is not registered, or was registered retrospectively, please explain the reasons for this.
Images of, or information about, identifiable individuals
It is the author’s responsibility to obtain consent from patients and other individuals for use of information, images, audio files, interview transcripts, and video clips from which they may be identified. To ensure we have the rights we require, please provide a signed Patient consent form in all instances. If the person is a minor, consent must be obtained from the child’s parents or guardians.
If the person is deceased, it is both essential and ethical that you obtain consent for use from the next of kin. If this is impractical you need to balance the need to use the photo against the risk of causing offence. In all cases ensure you obscure the identity of the deceased.
If using older material, or for material obtained in the field, for which signed release forms are, for practical purposes, unobtainable, you will need to confirm in writing that the material in question was obtained with the person’s understanding that it might be published.
Ethics Committee Approval
Details should be given in the methods section of the approval of the study protocol by an ethics committee or similar body and the approval number or identification code should be provided. The ethics committee that approved the protocol should be described in sufficient detail to allow the committee to be identified.
Guidelines on Publication Ethics
For full guidance on all aspects of Publication Ethics, please see here.
Guidelines on Reporting
For guidance on how to enhance the quality and transparency of health research, please see here.
January 17th 2017
Download the App
New Android App Available!
iOS App for iPad or iPhone